Monday , December 18 2017
Home / Letter From The Editor / Letter from the Editor #581: Exenatide News and Type 1 News from the ADA

Letter from the Editor #581: Exenatide News and Type 1 News from the ADA

There was a news release that caught my attention this past week. Eli Lilly announced that the Exenatide tQT Study Showed No Prolongation of QT Interval (See this week’s Item #1). Back in March most of us thought that the FDA would approve the once weekly dose, but instead they asked for this tQt test at the last minute. Now that the data is out and is positive, one can only wonder what the FDA will do when Lilly, Amylin and Alkemes submit the data in the 3rd Quarter of this year.

Over the past few weeks we have brought you great information from the Scientific Sessions of the ADA and most of it has been around type 2 diabetes. After receiving a few comments, our publisher, Steve Freed, put his staff to work researching the hot items and ideas for type 1 diabetes and they have prepared a great feature for you. Click here to read, ADA: Advances in Treating Type 1 Diabetes: An Overview of the Latest Developments.

Our president, Andrew Young, has type 1 diabetes and often is concerned about hypoglycemia, which is why he insisted that we include some information about the GlucaPen™ a new device that allows you to deliver glucagon without prior mixing.

*****

Announcements:

TCOYD Mini-Series Event, San Diego, California, July 27, 2011, 6:30 – 8:30 pm

Join Steven Edelman, MD, and Robert Henry, MD, at the Preuss School Auditorium in San Diego, California, for an evening focused on the latest information on A New Generation of Drugs: Approved and In Development.

Please answer this week’s poll: If the GLP-1 drugs were approved for pre-diabetes, would you recommend them?

View last week’s poll results.

*****************************
We can make a difference!
*****************************

Check out this week’s “Test Your Diabetes Knowledge” question!

Dave Joffe, Editor-in-chief